ORGOVYX from Myovant Sciences is a gonadotropin-releasing hormone receptor antagonist that is FDA indicated to treat adults with advanced prostate cancer.
FDA approved the drug in December, 2020. In a press release, Richard Pazdur, FDA’s acting director of the Office of Oncologic Diseases, noted that ORGOVYX is “the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require administration by a health care provider.” Pazdur went on to point out that the oral therapy could reduce risk during the COVID-19 pandemic.